Protein-based therapeutics have led to new paradigms in disease treatment. Projected to be
half of the top ten selling drugs in 2023, proteins have emerged as rivaling and, in some …

Protein and peptide drugs are predominantly administered by injection to achieve high
bioavailability, but this greatly compromises patient compliance. Oral and transdermal drug …

Protein-based bioactive coatings have emerged as a versatile and promising strategy for
enhancing the performance and biocompatibility of diverse biomedical materials and …

Highlights•A variety of albumin-binding moieties (ABMs) have been developed for half-life
extension of short-lived drugs.•Various drugs can incorporate a selected ABM for in situ HSA …

The impermeable barriers of solid tumors restrict the co‐delivery of protein‐based drugs and
chemotherapeutics for cancer treatment. Therefore, we developed a ZIF‐DOX/RA@ DG …

Over the last few decades, design and discovery of chemical reactions that enable
modification of proteins at pre-determined sites have been the focus of synthetic organic …

Simple Summary Monoclonal antibody-bearing radionuclides have been under clinical
investigation over the last two decades for their use in theranostic (diagnostic and …

Abstract Currently, although> 10 antibody− drug conjugates (ADCs) are available in the
market, most of them (10 ADCs) have broad drug distribution, thereby potentially limiting …

Mitigation of biofouling and the host's foreign body response (FBR) is a critical challenge
with biomedical implants. The surface coating with various anti-fouling materials provides a …

Currently, there are over 100 antibody-based therapeutics on the market for the treatment of
various diseases. The increasing importance of antibody treatment is further highlighted by …